Liraglutide sits inside the glucagon-like peptide-1 receptor agonist class, and its standing against semaglutide and the wider GLP-1 field comes down to potency, dosing frequency, and the weight of each agent's outcomes data. Both are FDA-approved and backed by human clinical trials; the honest bottom line is that semaglutide generally posts larger weight and HbA1c reductions at its higher doses, while liraglutide holds the longest real-world record in the class. Tirzepatide, a dual GIP and GLP-1 agonist, now sets the efficacy ceiling both are measured against.
Liraglutide is a once-daily GLP-1 receptor agonist with a roughly 13-hour half-life, while semaglutide's week-long half-life allows once-weekly injection and generally larger weight and HbA1c reductions at its higher approved doses.
Both molecules are acylated analogs of native GLP-1, but semaglutide is engineered harder for longevity. The distance between a 13-hour half-life and a week-long one is not a detail; it is what separates a daily injection from a weekly one and what makes an oral version chemically possible for one agent and not the other.
| Property | Liraglutide | Semaglutide |
|---|---|---|
| Amino-acid changes | One substitution | Two substitutions |
| Fatty-acid chain | C-16, glutamic acid linker | C-18 diacid plus spacer |
| Half-life | ~13 hours | ~165 to 184 hours (about a week) |
| Dosing frequency | Once daily | Once weekly; oral tablet available |
| Time to steady state | A few days | Several weeks |
Liraglutide's single amino-acid substitution and C-16 fatty-acid chain yield a half-life near 13 hours, while semaglutide's two substitutions and longer C-18 diacid chain extend its half-life to roughly 165 to 184 hours.
On weight, the published head-to-head record favors semaglutide by a wide margin. In the obesity trials the two agents were not close, and a direct comparison at their weight-management doses roughly doubled the mean loss on semaglutide's side.
At their approved obesity doses, once-weekly semaglutide 2.4 milligrams produced mean weight loss of 15 to 17 percent over 68 weeks versus roughly 6 to 8 percent for liraglutide 3.0 milligrams daily.
For glucose control the pattern repeats, though the gap is narrower. Both agents lower HbA1c meaningfully across their respective trial programs, and both do it in a glucose-dependent way that keeps the intrinsic risk of hypoglycemia low when used alone or with metformin.
| Measure | Liraglutide | Semaglutide |
|---|---|---|
| HbA1c reduction | ~1.0 to 1.5 points (LEAD program) | ~1.5 to 1.8 points (SUSTAIN program) |
| Direct comparison | 1.2 mg arm | 1.0 mg lowered HbA1c more (SUSTAIN 10) |
| Hypoglycemia risk | Low as monotherapy or with metformin | Low as monotherapy or with metformin |
Across their trial programs semaglutide reduced HbA1c by roughly 1.5 to 1.8 percentage points versus 1.0 to 1.5 for liraglutide, and in the direct SUSTAIN 10 comparison semaglutide 1.0 milligram lowered HbA1c more than liraglutide 1.2 milligrams.
Cardiovascular outcomes are now central to how these agents are ranked, and both carry supportive data from dedicated trials. The benefit is treated as agent-specific rather than automatic across the class, because not every GLP-1 agonist has reproduced it.
The LEADER trial reported liraglutide reduced major adverse cardiovascular events by about 13 percent and SUSTAIN 6 reported semaglutide reduced the same composite by about 26 percent in people with type 2 diabetes at elevated cardiovascular risk.
Tolerability across the class is dominated by gastrointestinal effects, and the differences between agents are more about magnitude and timing than kind. The more consequential caution is the class-wide boxed warning, which rules these agents out for a defined group regardless of which one is chosen.
Every GLP-1 receptor agonist in this class carries a boxed warning for thyroid C-cell tumors and is contraindicated in people with a personal or family history of medullary thyroid carcinoma or multiple endocrine neoplasia type 2.
Administration is one of the clearest practical dividing lines in the class. It ranges from twice-daily to once-weekly injections and, for semaglutide alone, a daily oral tablet bound by a strict fasting window.
Liraglutide is a once-daily subcutaneous injection, semaglutide is once-weekly with the class's only oral tablet, and other agents span twice-daily exenatide to once-weekly dulaglutide and extended-release exenatide.
Cost is frequently the deciding factor between otherwise reasonable options, because every branded GLP-1 agonist sits at a high list price. Coverage, not efficacy, often determines which agent a patient actually receives.
Branded GLP-1 agonists commonly list from several hundred to over a thousand dollars per month before insurance, and coverage is typically broader for the type 2 diabetes indication than for weight management.
The incretin landscape stretches well beyond these two, and it reshapes how each is ranked. Tirzepatide's dual mechanism has effectively set a new efficacy ceiling, while the older pure GLP-1 agonists fill out the lower rungs.
Tirzepatide, a dual GIP and GLP-1 receptor agonist, has posted mean weight loss into the 20 percent range and the largest HbA1c reductions in the incretin class, setting the efficacy ceiling that pure GLP-1 agonists like liraglutide and semaglutide are measured against.
Regulatory labeling separates these agents in ways that can mislead, because the same active ingredient is often sold under different brand names for different uses. Approvals are indication-specific, so a product cleared only for diabetes is used off-label when prescribed purely for weight loss, which carries coverage and liability consequences.
Each GLP-1 product is approved for specific indications under distinct brand names, so a product cleared only for type 2 diabetes is prescribed off-label when used purely for weight loss, with direct coverage and liability implications.
Educational use only. This article describes what the published scientific and clinical literature reports about Liraglutide, semaglutide, and other GLP-1 medications. It is not medical advice, and it does not recommend, prescribe, or tell anyone to use anything described here. The regulatory status shown at the top of this page reflects what the record showed on the date given there and can change. mdpep.com does not sell any substance described here, does not endorse human use of it, and does not direct anyone to obtain it.
This is not guidance for your situation. Nothing here accounts for your medical history, your current medications, or anything else specific to you, and none of it should be used to make a decision about your own health.
Affiliate disclosure. Some links on this site are affiliate links, and mdpep.com may earn a commission when they are used. That never affects what is written here, it is not an endorsement of any vendor, and it is not a statement that anything described on this page is available to buy.
Every claim here ties to a named primary source and a date, written as plain documentation with nothing for sale. That is how MD PEP covers the whole peptide market.
